Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent Glioblastoma
Phase of Trial: Phase I/II
Latest Information Update: 05 Apr 2018
Price : $35 *
At a glance
- Drugs TPI 287 (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cortice Bioscience; Cortice Biosciences
- 30 Mar 2018 Planned End Date changed from 1 Feb 2018 to 1 Mar 2019.
- 30 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Mar 2019.
- 30 Mar 2018 Status changed from recruiting to suspended due to financial reasons.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History